NSE: METROPOLIS · BSE: 542650 · ISIN INE112L01020
Metropolis Healthcare Limited stock analysis
Metropolis Healthcare Limited ranks #685 in the TickerSutra evidence-ranked universe with a score of 61/100 and 95% data confidence. The latest captured fundamentals show ROCE of 17.8%, quarterly sales growth of 16.6% and quarterly profit growth of 25.8%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.15×
- Strong CFO/EBITDA of 0.86×
- Institutional ownership is rising
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,228cr | ₹348cr | ₹215cr | 28.0% |
| 2023 | ₹1,148cr | ₹293cr | ₹143cr | 26.0% |
| 2024 | ₹1,208cr | ₹288cr | ₹128cr | 24.0% |
| 2025 | ₹1,331cr | ₹308cr | ₹146cr | 23.0% |
| 2026 | ₹1,646cr | ₹406cr | ₹191cr | 25.0% |
| TTM | ₹1,710cr | ₹422cr | ₹203cr | 25.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Metropolis Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
RoutineAlteration Of Capital and Fund Raising-XBRLNSE · 9 Sept 2026 · Structured filingMetropolis Healthcare Limited has informed the Exchange regarding Allotment of Securities
Metropolis Healthcare Limited has informed the Exchange regarding Allotment of Securities
Open original XBRL sourceMetropolis Healthcare Limited has informed the Exchange about allotment of 66,312 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020.
RoutineMetropolis Healthcare Ltd - 542650 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSBSE · 9 Sept 2026Allotment of 66,312 equity shares under the Metropolis- Restrictive Stock Unit Plan, 2020
MANAGEMENT COMMENTARY
Signals from filed documents
You know, in any industry, like I mentioned, we have - in my mind, a 10 - 20 years structural journey ahead. Can we continue to build operating leverage? Can you continue to keep building margins out?
For us, we are not going to have that impact, you know, from Q3 onwards. So, 14%-15% guidance we suggested without any price increase, but we delivered 17% in the last quarter And we very clearly see opportunity because for us both B2C and B2B engines are firing, you know, both in the Speciality as well as TruHealth is firing. All the four regions are doing well for us, and the Tier 1, Tier 2, Tier 3, all the, you kn
So, we clearly see an opportunity to have the growth story getting better as we go forward. I'll now request Sameer to talk about our, you know, plans around the margin improvement. So, I think you all heard about our growth ambition and the key growth engine across network expansion, genomics specialty, TruHealth, and inorganic growth technology and let me put this all together and talk about the financial perspecti
So, the entire piece where we , it was vendor dependent, what Metropolis was doing by the vendors in terms of technology, we are building a team in -house where also, because recently one of the, with the AI and all that, the development times are all shrinking. So what we are confident is that the number of projects that we can take up in this coming year will be much higher and next year, when we go to the next yea
And that's why you see tier 3 also growing as well as the specialty growing because of the healthcare access as well as the menu and the doctors and the super-specialists being available in those tier 2, tier 3 towns as well. Ameera Shah: I am not mistaken, I think your question is around does Tier 3 make lower margins than metros? And the assumption is that we are probably doing routine in Tier 3.
That's not the moat in the business and as we go along, I'll explain to you what the moat for Metropolis is. We operate in 750 towns in India alone, plus 5 international markets where we actually have our own labs and our own people. Then there are many other countries who outsource specialized testing to us where we use our assets in India and including these 5 international countries, they send about 30%-40% of the
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…